Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Siemens, takes on Prowess DAO tech

This article was originally published in Clinica

Executive Summary

Siemens Healthcare has teamed up with radiotherapy company Prowess in a bid to develop new radiation oncology treatment planning software. The exclusive partnership will see Siemens integrate into its linear accelerators Prowess' direct aperture optimisation (DAO) technology. The DAO technology allows clinicians to make on-line corrections to the treatment plan based on pre-treatment CT scans, just before the patient is about to receive therapy. This combination is designed to help users reduce the amount of equipment in the workplace and cut down overall treatment times. Chico, California-based Prowess is currently developing the DAO-based Plan-to-Patient software for radiation therapy, which is undergoing clinical assessment and is scheduled to become commercially available in Q2 2008. According to Siemens, the Plan-to-Patient device works in conjunction with its CTVision system, an image-guided radiation therapy device.

You may also be interested in...

Coronavirus Update: Novartis Targets COVID-19 Cytokine Storm With Jakavi

Jakavi joins the likes of Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients

As China Rushes Medical Supplies To World, Quality Issues Resurface

As China is poised to supply globally medical products to fight coronavirus, a battle to banish its image of poor product quality is on.

UK Regulator Puts Energies Into COVID-19 While Other Services May Take Longer

With finite resources, the UK’s regulatory agency responsible for health care products is rapidly addressing COVID-19 medtech issues. But shifting its focus will cause delays elsewhere.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts